Efficacy of Osimertinib in Patients With Postoperative Recurrent Non–Small‐Cell Lung Cancer Harboring Sensitizing EGFR Mutations
Thoracic Cancer · 2026-04 · 17 (8)
DOI: 10.1111/1759-7714.70285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 24.04.2026. Verfasst von Yuko Iida und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. Hauptthemen laut MEDLINE: Aniline Compounds, Carcinoma, Non-Small-Cell Lung, Acrylamides, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The efficacy of osimertinib in patients with postoperative recurrent non–small‐cell lung cancer (NSCLC) compared to those with Stage IV NSCLC harboring epidermal growth factor receptor ( EGFR ) mutations remains unclear.
Methods
This study evaluated the efficacy of osimertinib in patients with postoperative recurrent EGFR ‐mutated NSCLC. We retrospectively evaluated patients with NSCLC harboring EGFR mutations (exon 19 deletion or L858R mutation) who received osimertinib between September 2018 and July 2022 at a single institution. The efficacy of osimertinib was compared between patients with postoperative recurrent NSCLC (postoperative group) and those with Stage IV NSCLC (Stage IV group).
Results
Among a total of 172 patients treated with osimertinib, 52 were classified into the postoperative group and 120 into the Stage IV group. The response rate (58.1% vs. 61.8%, p = 0.836) and progression‐free survival (hazard ratio [HR]: 0.854, 95% confidence interval [CI]: 0.558–1.306, p = 0.465) were not significantly different between the postoperative and Stage IV groups. Overall survival (OS) was significantly longer in the postoperative group than in the Stage IV group (median: 39.2 months and 28.5 months, respectively; HR: 0.521, 95% CI: 0.293–0.927, p = 0.024). In the multivariable analysis of OS, postoperative recurrent disease and performance status were independent favorable prognostic factors.
Conclusions
Postoperative recurrent disease was an independent favorable prognostic factor in patients with NSCLC harboring EGFR mutations treated with osimertinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
- Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
- Department of Biostatistics, Clinical Research Support Center, Shizuoka Cancer Center, Shizuoka, Japan.
- Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
ORCID-Profile: Yuko Iida, Meiko Morita, Kazushige Wakuda, Tateaki Naito, Haruyasu Murakami
Zitieren
APA
Iida, Y., Kenmotsu, H., Mori, K., Morita, M., Sekikawa, M., Yabe, M., Doshita, K., Miura, K., Kodama, H., Morikawa, N., Mamesaya, N., Kobayashi, H., Ko, R., Wakuda, K., Ono, A., Naito, T., Murakami, H., Ohde, Y., Gon, Y., & Takahashi, T. (2026). Efficacy of Osimertinib in Patients With Postoperative Recurrent Non–Small‐Cell Lung Cancer Harboring Sensitizing EGFR Mutations. Thoracic Cancer, 17(8). https://doi.org/10.1111/1759-7714.70285
Vancouver
Iida Y, Kenmotsu H, Mori K, Morita M, Sekikawa M, Yabe M, et al. Efficacy of Osimertinib in Patients With Postoperative Recurrent Non–Small‐Cell Lung Cancer Harboring Sensitizing EGFR Mutations. Thoracic Cancer. 2026;17(8). doi:10.1111/1759-7714.70285
BibTeX
@article{Iida2026,
author = {Iida, Yuko and Kenmotsu, Hirotsugu and Mori, Keita and Morita, Meiko and Sekikawa, Motoki and Yabe, Michitoshi and Doshita, Kosei and Miura, Keita and Kodama, Hiroaki and Morikawa, Noboru and Mamesaya, Nobuaki and Kobayashi, Haruki and Ko, Ryo and Wakuda, Kazushige and Ono, Akira and Naito, Tateaki and Murakami, Haruyasu and Ohde, Yasuhisa and Gon, Yasuhiro and Takahashi, Toshiaki},
title = {Efficacy of Osimertinib in Patients With Postoperative Recurrent Non–Small‐Cell Lung Cancer Harboring Sensitizing EGFR Mutations},
journal = {Thoracic Cancer},
year = {2026},
volume = {17},
number = {8},
doi = {10.1111/1759-7714.70285}
}
EUVIMED